Articles tagged "Hepatitis C"

2020 American Transplant Congress
Experiences and Challenges Faced by Organ Transplant Recipients with Donor-Derived Hepatitis C Virus Infection
K. Prakash¹, C. Ramirez-Sanchez¹, S. I. Ramirez¹, C. Logan¹, N. Law¹, K. Mekeel², V. Pretorius², S. Aslam¹
¹Medicine, University of California San Diego, San Diego, CA, ²Surgery, University of California San Diego, San Diego, CA
*Purpose: Recently, transplantation of organs from viremic donors with hepatitis C virus (HCV-V) has increased. Currently, there is a lack of standardization of consent forms…
2020 American Transplant Congress
Re-Examining Sex-Based Differences in Liver Transplant Outcomes for HCV Cirrhosis
D. Yoeli¹, R. Choudhury¹, H. Moore¹, A. Sauaia¹, M. Simpson², E. Pomfret¹, T. Nydam¹
¹Transplant Surgery, University of Colorado, Aurora, CO, ²Transplant Surgery, Lahey Hospital and Medical Center, Burlington, MA
*Purpose: Previous studies have demonstrated that female liver transplant recipients with hepatitis C (HCV) are at increased risk for graft failure due to disease recurrence…
2020 American Transplant Congress
Kidney Transplantation from Hepatitis C Infected Donors to Hepatitis C Negative Recipients: Does Organs Selection Matter?
B. Rawashdeh¹, L. Luu¹, Z. Sahli¹, E. McCracken¹, A. Doyle², K. Brayman¹, A. Agarwal¹
¹Transplant Surgery, University of Virginia, Charlottesville, VA, ²Division of Transplant Nephrology, University of Virginia, Charlottesville, VA
*Purpose: Recently, there has been a marked increase in the availability and use of kidneys from hepatitis C virus (HCV) positive deceased donors for transplantation.…
2020 American Transplant Congress
Incidence of Cytomegalovirus Infection in Deceased Donor Kidney Transplantation from Hepatitis-C Antibody Positive Donors to Hepatitis-C Antibody Negative Recipients: A National Registry Analysis
M. Yazawa¹, T. Fülöp², O. Cseprekal³, M. Talwar¹, V. Balaraman¹, A. Bhalla¹, A. Azhar¹, C. P. Kovesdy⁴, J. D. Eason¹, M. Z. Molnar¹
¹James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN, ²Division of Nephrology, Department of Medicine, Medical University of South Carolina, South Carolina, SC, ³Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary, ⁴Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN
*Purpose: Deceased donor kidney transplantation (KT) from hepatitis C (HCV) infected donors into HCV uninfected recipients (HCV D+/R-) will be the standard of care in…
2020 American Transplant Congress
Using HCV Infected Organs and the Challenge of Third-Party Payers
R. Daloul, A. Michaels, L. Sobotka, T. Pesavento, K. Washburn
Comprhensive Transplant Center, The Ohio State University, Columbus, OH
*Purpose: The practice of transplanting organs from hepatitis C viremic donors (HCV NAT+) into negative recipients hinges on the ability to ensure direct acting antiviral…
2020 American Transplant Congress
Exploring the Uneven Geographic Distribution of Hepatitis C-Viremic Deceased Donors in the US
A. Ohringer, D. Goldberg
University of Miami, Miami, FL
*Purpose: There has been a marked increase in the utilization of organs from hepatitis C virus (HCV) viremic donors due to the rise of drug-related…
2020 American Transplant Congress
A Successful Kidney Transplantation from Hepatitis C NAT Positive Deceased Donor to an HIV Positive Recipient with Previous History of Treated HCV Infection
R. H. Naik, S. Shawar, H. Schaefer
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Due to a shortage of deceased donor kidney organs, increased waiting times have been associated with adverse outcomes post kidney transplantation. The recent breakthrough…
2020 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
H. Joharji, D. Alkortas, A. Ajlan, E. Devol, M. Ahmed, F. Aba Al-Khail, H. Elsiesy, M. Alsebayel, H. Alashgar, M. Alquaiz, W. Alhamoudi, A. Almoshishir, A. Aljedai
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
*Purpose: Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of HCV has shifted in the last few…
2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
S. Bova¹, A. Cameron¹, C. Durand¹, J. Katzianer², M. LeGrand², L. Boyer¹, J. Glorioso³, L. P. Toman¹
¹The Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins Home Care Group, Baltimore, MD, ³Thomas Jefferson Univeristy Hospital, Philadelphia, PA
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…
2019 American Transplant Congress
Results from the LIVE-C Free Trial
J. N. Fleming¹, D. DuBay¹, N. L. Jonassaint², R. S. Satoskar³, K. D. Chavin⁴
¹Medical University of South Carolina, Charleston, SC, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Medstar Georgetown Medical Center, Washington, DC, ⁴University Hospital, Cleveland, OH
*Purpose: Ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) has shown excellent results post-liver transplant. However, due to the poor tolerability of RBV, it is commonly…